The evolving landscape of immunotherapy in solid tumors
Jessica M. Keilson, Hannah M. Knochelmann, Chrystal M. Paulos, Ragini R. Kudchadkar, Michael Lowe
Abstract
While surgical resection, local and cytotoxic therapies have long formed the basis of cancer care, immunotherapy now plays a key role in supplementing and even replacing these agents in the first line. Here we review the early success of programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 blockade and discuss biomarkers of therapeutic response. We next highlight a select group of novel targets in Phase III trials both as monotherapies and in combination with PD-1 inhibitors. Finally, we discuss innovations which seek to improve outcomes in therapy-resistant solid tumors.
Topics & Concepts
MedicineImmunotherapyCytotoxic T cellBlockadeFirst lineCancerOncologyCancer researchInternal medicineReceptorBiochemistryChemistryIn vitroCancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune Responses